What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease? by Kent, Seamus et al.
Kent et al. BMC Nephrology  (2015) 16:65 
DOI 10.1186/s12882-015-0054-0RESEARCH ARTICLE Open AccessWhat is the impact of chronic kidney disease
stage and cardiovascular disease on the annual
cost of hospital care in moderate-to-severe
kidney disease?
Seamus Kent1, Iryna Schlackow1, Jingky Lozano-Kühne1, Christina Reith2, Jonathan Emberson2, Richard Haynes2,
Alastair Gray1, Alan Cass3, Colin Baigent2, Martin J Landray2, William Herrington2†, Borislava Mihaylova1*†
and on behalf of the SHARP Collaborative GroupAbstract
Background: Reliable estimates of the impacts of chronic kidney disease (CKD) stage, with and without cardiovascular
disease, on hospital costs are needed to inform health policy.
Methods: The Study of Heart and Renal Protection (SHARP) randomized trial prospectively collected information
on kidney disease progression, serious adverse events and hospital care use in a cohort of patients with
moderate-to-severe CKD. In a secondary analysis of SHARP data, the impact of participants’ CKD stage, non-fatal
cardiovascular events and deaths on annual hospital costs (i.e. all hospital admissions, routine dialysis treatments and
recorded outpatient/day-case attendances in United Kingdom 2011 prices) were estimated using linear regression.
Results: 7,246 SHARP patients (2,498 on dialysis at baseline) from Europe, North America, and Australasia contributed
28,261 years of data. CKD patients without diabetes or vascular disease incurred annual hospital care costs ranging
from £403 (95% confidence interval: 345-462) in CKD stages 1-3B to £525 (449-602) in CKD stage 5 (not on
dialysis). Patients in receipt of maintenance dialysis incurred annual hospital costs of £18,986 (18,620-19,352) in
the year of initiation and £23,326 (23,231-23,421) annually thereafter. Patients with a functioning kidney transplant
incurred £24,602 (24,027-25,178) in hospital care costs in the year of transplantation and £1,148 (978-1,318) annually
thereafter. Non-fatal major vascular events increased annual costs in the year of the event by £6,133 (5,608-6,658) for
patients on dialysis and by £4,350 (3,819-4,880) for patients not on dialysis, and were associated with increased costs,
though to a lesser extent, in subsequent years.
Conclusions: Renal replacement therapy and major vascular events are the main contributors to the high hospital
care costs in moderate-to-severe CKD. These estimates of hospital costs can be used to inform health policy
in moderate-to-severe CKD.
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In the United Kingdom (UK), the age-standardized
prevalence of chronic kidney disease (CKD) stages 3 to 5
not on renal replacement therapy (RRT) has been esti-
mated at 11% for females and 6% for males [1]. The
prevalence of end-stage renal disease requiring RRT is
0.1%, of which 49% have a functioning kidney transplant,
44% are on hemodialysis and 8% use peritoneal dialysis
[2]. The annual cost of CKD to the National Health
Service (NHS) in England in 2009-2010 was estimated
at £1.45 billion (1.3% of total NHS expenditure), with the
cost of RRT accounting for more than half of this total [3].
The increased risk of vascular and nonvascular morbidity
and mortality conferred by CKD [4-8] is a key determin-
ant of these substantial healthcare costs.
The estimate of NHS expenditure on CKD in England
in Kerr et al. [3] was derived using a variety of secondary
sources, including the primary care Quality and Outcomes
Framework, NHS Blood and Transplant, the UK Renal
Registry, and NHS Reference costs. The costs of cardio-
vascular disease attributable to CKD were calculated by
attaching unit costs estimated in general population set-
tings to the estimated excess numbers of myocardial in-
farctions and strokes in people with CKD. A more reliable
method is to use individual CKD patient data to directly
estimate per person costs of the disease. An individual
patient data approach has been employed in a number
of CKD cost studies [9-14]; however, none of these esti-
mated the separate contributions of CKD progression and
cardiovascular events on hospital care costs. We use indi-
vidual patient data from the Study of Heart and Renal
Protection (SHARP) to estimate the annual hospital care
costs (defined as the cost of all hospital admissions,
routine dialysis treatments and any recorded outpatient/
day-case attendances) associated with CKD stage and car-
diovascular complications in CKD, and to develop a UK
annual cost prediction model in CKD.
Methods
SHARP study population
Details of the design of the SHARP trial and its main re-
sults have been reported previously [15,16]. Briefly, indi-
viduals aged 40 years or over were eligible to participate
if they had more than one previous measurement of serum
or plasma creatinine of at least 1.7 mg/dL (150 μmol/L) in
men or 1.5 mg/dL (130 μmol/L) in women, or were receiv-
ing maintenance dialysis. Patients with prior myocardial
infarction or coronary revascularization were excluded.
Between 2003 and 2006, 9,270 patients from 18 countries
in Europe, North America, Asia, and Australasia pro-
vided written informed consent and were randomized
and followed for a median of 4.9 years until the end
of the study in 2010. Ethical approval for SHARP was
given by the Thames Valley Multicentre Research Ethicscommittee. The 1,928 (21%) patients recruited in Asia
were excluded from the analysis presented here be-
cause there were important differences in the case-
mix of hospital events and substantially lower rates of
hospitalization for major vascular events, compared to
patients from other regions.
Serious adverse events
Following randomization, patients were followed up at
study clinics at 2 and 6 months, and then every 6 months.
At each follow-up visit, information on all hospital admis-
sions and possible study outcomes was recorded. If a
patient became unwilling or unable to attend follow-up
visits, information was sought from them (or a relative or
carer) by telephone or from their doctor until the sched-
uled study end. Further information was sought from
hospital records and other appropriate sources for all
events that might represent an important study outcome.
Trained clinicians adjudicated important study outcomes in
accordance with pre-specified definitions. All diagnoses were
subsequently coded into the International Classification
of Diseases (ICD-10) system and all procedures into the
Operating Code Supplement (OPCS-4.5) system. For the
purpose of the hospital cost analysis, follow-up time was di-
vided into annual periods from the date of randomization
to the end of study. Only fully observed annual periods and
annual periods shorter than one year due to death were in-
cluded in the cost analysis.
Cardiovascular disease
Cardiovascular disease and vital status were determined
for each patient at the end of each annual period and cate-
gorized into a mutually exclusive hierarchy (in descending
order): i) vascular death during the current annual period;
ii) non-vascular death during the current annual period;
iii) a non-fatal major vascular event (MVE: defined as cor-
onary death, non-fatal myocardial infarction, any arterial
revascularization procedure, or stroke) during the current
annual period; iv) most recent non-fatal MVE in the
preceding annual period; v) most recent non-fatal MVE
occurred in the annual period before last; vi) most recent
non-fatal MVE occurred more than two annual periods
previously; vii) prior vascular disease at randomization
but no MVE since; and, viii) no vascular disease at
randomization and no subsequent MVE.
Chronic kidney disease staging
Renal status was determined at each follow-up visit using
local measurements of serum/plasma creatinine, or, where
relevant, current RRT modality. For each annual period,
the mean of all recorded creatinine results in the period
was used to calculate the CKD Epidemiology Collaboration
(CKD-EPI) estimated glomerular filtration rate (eGFR)
[17] and categorize patients into the following mutually
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CKD stage 4 (eGFR ≥15, <30 ml/min/1.73 m2); CKD stage
5 not on RRT (eGFR <15 ml/min/1.73 m2); maintenance
dialysis initiated in the current annual period; mainten-
ance dialysis initiated in a preceding annual period; kidney
transplantation in the current annual period; or, functional
kidney transplant from an earlier annual period. In the
cases in which information was absent, the latest informa-
tion on CKD stage was carried forward for up to two years
(for 3% of annual periods).
Hospital care use and costs
All serious adverse events related to hospital care use
were classified into one of four mutually exclusive cat-
egories: i) atherosclerotic events; ii) non-atherosclerotic
vascular events; iii) renal events; or iv) other events
(i.e. non-vascular, non-renal events) [see Additional file 1:
Table S1 for full description]. Hospital episodes (inpatient
admissions, day case, or outpatient attendances) were
formed from serious adverse events with overlapping du-
rations. Where a hospital episode involved more than one
event, the episode was classified according to the (de-
scending) hierarchical order above. Each patient’s hospital
episodes, alongside information on their age and co-
morbidities, were mapped into 2010-11 UK Healthcare
Resource Groups [18] with UK Hospital Trust costs [19]
(the approach to costing recommended by the National
Institute for Health and Care Excellence [20]). Although
the data collected in the study did not allow the identifica-
tion of finished consultant episodes (FCE) for hospital
care, which is used as the unit for costing healthcare activ-
ity in the UK, it should be noted that more than 90% of
hospital admissions in the UK contain only one FCE [21].
We also established the cost of the episode using the most
resource intensive of the events experienced, further redu-
cing the extent of any underestimation.
Information on routine dialysis sessions was not recorded
in SHARP. Instead, the 2010-11 UK costs of maintenance
dialysis treatment were estimated for each patient based on
their six-monthly dialysis status assuming thrice weekly
hemodialysis sessions (£24,973 per annum) and daily peri-
toneal dialysis sessions (£20,449 per annum) [19,22].
Statistical methods
A wide range of baseline socio-demographic and clinical
patient characteristics, annually updated CKD stage and an-
nually updated cardiovascular event history were related to
annual hospital care costs using a linear regression model.
The final statistical model was selected from a wider range
of candidate models using common specification tests [23]
and a comparative assessment of each model’s predictive
performance. A backward-stepwise selection procedure
using statistical criteria was used to retain important co-
variates and interactions (see Additional file 1: Statisticalappendix for full details). Standard errors of the parameter
estimates in the regression model were adjusted for the
multiple annual cost observations per patient [24]. Mean
annual hospital costs were calculated for patient profiles
by CKD stage and history of cardiovascular events. Mean
absolute prediction error was calculated using cross-
validation based on 1,000 randomly split samples [25]. All
analyses were performed using R 3.0.0 [26].
Results
After excluding the 5,847 annual periods with incomplete
information due to the end of study follow up, 28,261 an-
nual periods of observation were available across 7,246
patients recruited in non-Asian countries. Of these pa-
tients, 5,083 (70%) were recruited in Europe, 1,302 (18%)
in Australasia and 861 (12%) in North America. Mean age
was 63 (standard deviation 12) years, 4,652 (64%) were
male, 1,116 (15%) had established vascular disease and
1,439 (20%) had diabetes mellitus at baseline. CKD stage
data were recorded in 27,327 (97%) annual periods. 4,739
(65%) patients were not on RRT, of which 1,494 (32%)
were in CKD stages 1-3B (mean eGFR = 37.6 mL/min/
1.73 m2), 2,228 (47%) in CKD stage 4 and 1,017 (21%) in
CKD stage 5. 2,498 (34%) patients were on mainten-
ance dialysis at baseline, of which 2,076 (83%) were
on hemodialysis and 422 (17%) on peritoneal dialysis
(Table 1). By the end of the cost study period, 4,013 (55%)
patients were receiving RRT, including 800 (79%) of
those with CKD stage 5 at baseline, 621 (28%) of those
with CKD stage 4 and 85 (6%) of those in CKD stages
1-3B (Additional file 1: Table S2). During the study
follow-up there were 994 (3.5% per year) kidney trans-
plants and 1,362 (4.8% per year) patients started (or
restarted following a transplant failure) maintenance
dialysis (Table 2).
A total of 21,157 hospital care episodes were recorded
across the 7,246 study patients, an average of 0.77 epi-
sodes per patient per year (excluding routine dialysis
sessions). These included 0.33 episodes per year for non-
vascular/non-renal events, 0.32 episodes per year for renal
events, and 0.06 episodes per year for each of atheroscler-
otic and non-atherosclerotic vascular events per patient.
Worse kidney function at baseline was associated with
increased rates of hospital episodes of all types. Non-
vascular/non-renal episodes per patient-year ranged
from 0.24 among those in CKD stages 1-3B to 0.45 in
those on dialysis. Renal episodes (excluding routine dialy-
sis) were lowest in those in CKD stages 1-3B (0.06 per pa-
tient per year [ppy]) and greatest in those with CKD stage
5 not on RRT (0.59 ppy). Hospital episodes for both
atherosclerotic and non-atherosclerotic vascular disease
per patient-year more than doubled from 0.02-0.03 ppy
among those in CKD stages 1-3B to 0.08 ppy in those on
dialysis at baseline (Additional file 1: Table S3).
Table 1 Baseline characteristics of SHARP patients included in the cost analysis






(eGFR: <15 not on dialysis)
On dialysis
Number of patients 1,494 2,228 1,017 2,498 7,246
Men 1,078 (72%) 1,368 (61%) 599 (59%) 1,600 (64%) 4,652 (64%)
Age (years) 62 (11) 65 (12) 63 (12) 61 (12) 63 (12)
Prior vascular disease 189 (13%) 350 (16%) 147 (14%) 428 (17%) 1,116 (15%)
Prior diabetes mellitus 268 (18%) 454 (20%) 169 (17%) 546 (22%) 1,439 (20%)
Current smoker 205 (14%) 276 (12%) 133 (13%) 432 (17%) 1,048 (14%)
Body-mass index (kg/m2) 28.4 (5.3) 28.2 (5.8) 27.5 (5.5) 27.0 (5.9) 27.8 (5.7)
Diastolic blood pressure (mm Hg) 80 (13) 79 (13) 80 (12) 77 (13) 79 (13)
Systolic blood pressure (mm Hg) 138 (20) 138 (20) 141 (20) 137 (24) 138 (21)
Total cholesterol (mmol/L) 5.1 (1.1) 5.1 (1.1) 4.9 (1.2) 4.6 (1.2) 4.9 (1.2)
LDL cholesterol (mmol/L) 3.0 (0.8) 2.9 (0.8) 2.8 (0.9) 2.6 (0.9) 2.8 (0.9)
HDL cholesterol (mmol/L) 1.2 (0.3) 1.2 (0.3) 1.1 (0.3) 1.1 (0.4) 1.1 (0.3)
Triglycerides (mmol/L) 2.3 (1.6) 2.3 (1.4) 2.2 (1.4) 2.3 (1.9) 2.3 (1.6)
Renal status
On dialysis - - - 2,498 (100%) 2,498 (34%)
Hemodialysis - - - 2,076 (83%) 2,076 (29%)
Peritoneal dialysis - - - 422 (17%) 422 (6%)
Not on dialysis 1,494 (100%) 2,228 (100%) 1,017 (100%) - 4,739 (65%)
Estimated glomerular filtration rate (mL/min/1.732) 37.6 (6.5) 22.5 (4.3) 10.8 (2.7) - 24.8 (10.9)
Urinary albumin:creatinine ratio (mg/g)3
Median (IQR) 75 (16–328) 155 (36–592) 397 (124–1,204) - 156 (35–626)
<30 459 (36%) 426 (22%) 62 (7%) - 947 (23%)
≥30, ≤ 300 496 (38%) 820 (42%) 332 (37%) - 1,648 (40%)
>300 336 (26%) 722 (37%) 511 (56%) - 1,569 (38%)
Not available 203 260 112 - 584
Region of recruitment
Europe 1,022 (68%) 1,546 (69%) 730 (72%) 1,779 (71%) 5,083 (70%)
Australasia 260 (17%) 446 (20%) 187 (18%) 408 (16%) 1,302 (18%)
North America 212 (14%) 236 (11%) 100 (10%) 311 (12%) 861 (12%)
Data are n (%), mean (SD) or median (IQR); CKD = chronic kidney disease.
19 patients who received a transplant prior to randomization were excluded from the tabulation by baseline CKD stage.
2Predominantly CKD stage 3B (eGFR ≥30 to <45 ml/min/1.73m2).
3Percentages exclude patients for whom data were not available.
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nual periods, ranging from 24% of annual periods among
those in CKD stages 1-3B at baseline to 91% of annual
periods in those on maintenance dialysis at baseline
(Table 3). The average observed annual cost of hospital
care (including routine dialysis costs) was £9,977 (SE 69),
ranging from £1,055 (SE 46) for those in CKD stages 1-3B
through £12,952 (SE 185) for those with CKD stage 5 not
on RRT, to £20,511 (SE 93) for those on maintenance dia-
lysis at baseline.
From the large number of characteristics initially con-
sidered for inclusion in the cost model, only annuallyupdated CKD stage; history of cardiovascular disease
and prior diabetes mellitus at baseline; and interactions
between receiving dialysis and death and receiving dialy-
sis and experiencing a non-fatal major vascular event in
the current annual period, were retained in the model.
After accounting for these characteristics, patients with
CKD but without diabetes or vascular disease were esti-
mated to incur annual hospital care costs ranging from
£403 (95% confidence interval 345-462) in CKD stages
1-3B to £525 (449-602) in CKD stage 5. This was mainly
due to 19% of annual periods in CKD stage 5 containing
admissions for the formation/insertion of dialysis access,
Table 2 Number of patient years with events and use of renal replacement therapy by baseline CKD stage
Baseline CKD stage1 Overall
CKD 1-3B2 CKD 4 CKD 5 not on dialysis On dialysis
Number of patients 1,494 2,228 1,017 2,498 7,246
Vascular death 36 (0.6%) 92 (1.0%) 86 (2.2%) 235 (2.5%) 449 (1.6%)
Non-vascular death 97 (1.6%) 219 (2.5%) 151 (3.8%) 453 (4.9%) 920 (3.3%)
Non-fatal major vascular event in the current annual period 93 (1.5%) 222 (2.5%) 128 (3.2%) 385 (4.1%) 828 (2.9%)
Kidney transplantation in the current annual period 14 (0.2%) 142 (1.6%) 213 (5.4%) 625 (6.7%) 994 (3.5%)
On functioning kidney transplant from an earlier annual period 9 (0.1%) 126 (1.4%) 335 (8.5%) 1,170 (12.5%) 1,663 (5.9%)
Dialysis initiated during the current annual period 77 (1.3%) 548 (6.2%) 718 (18.2%) 18 (0.2%) 1,362 (4.8%)
On dialysis since an earlier annual period 44 (0.7%) 609 (6.9%) 1,337 (33.8%) 7,526 (80.6%) 9,516 (33.7%)
Data are the number of annual periods in which the defined event occurs or the RRT status, and percentage of all annual periods. In each annual period, each
participant on renal replacement therapy is classified into one of: (1) kidney transplantation in current annual period; (2) functioning kidney transplantation from
an earlier annual period; (3) dialysis initiated during the current annual period; and (4) on dialysis since an earlier annual period.
CKD = chronic kidney disease.
19 patients who received a transplant prior to randomization were excluded from the tabulation by baseline CKD stage.
2Predominantly CKD stage 3B (eGFR ≥30 to <45 ml/min/1.73m2).
Kent et al. BMC Nephrology  (2015) 16:65 Page 5 of 8compared to 2% in CKD stage 4. CKD patients in receipt
of maintenance dialysis incurred £18,986 (18,620-19,352)
costs in the year of initiation and £23,326 (23,231-
23,421) in each subsequent year. Average annual hospital
care costs in the year of transplantation were £24,602
(24,027-25,178), largely due to the costs of admission for
the transplant operation itself (UK hospital admission cost
for a kidney transplant was £20,798 [for a live donor] or
£19,417 [for a deceased donor; excluding all costs of dona-
tion and drugs] [19]), and £1,148 (978-1,318) in subse-
quent years (Table 4).
Death from vascular and nonvascular causes increased
hospital costs in the year of death by £1,137 (469-1,804)
and £1,391 (1,020-1,763) respectively. Non-fatal MVEs
increased annual hospital care costs in the year of the
event by £4,350 (3,819-4,880) for individuals not on dia-
lysis (including those with a functioning transplant) and
by £6,133 (5,608-6,658) for those receiving dialysis. The
effect of a vascular event on hospital costs remained, but
was diminished, in subsequent years: in the absence of
further MVEs, the effect of a non-fatal MVE on hospital
costs in the following year was £738 (351-1,126) and £172
(57-286) in each year thereafter. Having prior diabetes at
entry into the study was associated with additional annualTable 3 Observed annual hospital costs by baseline CKD stag
Baseline CKD stage1 Number of patients Years of follow-u
CKD 1-3B2 1,494 6,077
CKD 4 2,228 8,867
CKD 5 not on dialysis 1,017 3,954
Dialysis 2,498 9,339
All patients 7,246 28,261
CKD = chronic kidney disease; SE = standard error.
19 patients who received a transplant prior to randomization were excluded from t
2Predominantly CKD stage 3B (eGFR ≥30 to <45 ml/min/1.73m2).hospital costs of £171 (54-288) (Table 4). Estimates of
annual hospital costs were similar in a sensitivity ana-
lysis limited to data from the 1,910 patients recruited
in the United Kingdom. The inclusion of albuminuria
into the cost model was not found to offer further predict-
ive information for determining hospital care costs. The
final model had good aggregate and individual level pre-
dictive accuracy, with the mean absolute prediction error
estimated at 20% of the mean cost (see Additional file 1:
Table S5).
Discussion
A regression analysis on individual data from more than
7,000 CKD patients was used to estimate the annual
hospital care costs associated with CKD stage and car-
diovascular disease. The reported hospital cost model
(Table 4) allows the annual hospital care costs (in UK
2011 prices) to be estimated for a patient with moderate-
to-severe CKD if the CKD stage, cardiovascular disease
history, diabetes mellitus and vital status are known (see
Additional file 1: Table S4 for examples).
The predicted annual costs capture not only the direct
cost of an event (e.g. myocardial infarction or stroke),
but also costs of other related health problems in thee
p Years of follow-up
with hospital use, n (%)
Mean (SE) hospital cost per
person-year of follow-up
1,447 (24%) £1,055 (46)
3,379 (38%) £3,694 (84)
2,849 (72%) £12,952 (185)
8,543 (91%) £20,511 (93)
16,227 (57%) £9,977 (69)
he tabulation by baseline CKD stage.
Table 4 Estimated annual UK hospital care costs of chronic
kidney disease patients by stage of chronic kidney disease
and presence of cardiovascular complications
Annual hospital care costs (£, 95% CI) in the absence of diabetes
and cardiovascular complications
In CKD stage 1-3B1 £403 (345–462)
In CKD stage 4 £393 (343–444)
In CKD stage 5 £525 (449–602)
On functioning kidney transplant
from the current annual period
£24,602 (24,027-25,178)
On functioning kidney transplant from
an earlier annual period
£1,148 (978–1,318)
On maintenance dialysis initiated in
the current annual period2
£18,986 (18,620-19,352)
On maintenance dialysis initiated in an
earlier annual period2
£23,326 (23,231-23,421)
Additional annual hospital care costs associated with diabetes,
cardiovascular complications and death (£, 95% CI)
With prior diabetes3 £171 (54–288)
Died from vascular cause in the current
annual period
£1,137 (469–1,804)
Died from non-vascular cause in the
current annual period
£1,391 (1,020-1,763)
Experienced non-fatal MVE during the current
annual period, not on maintenance dialysis
£4,350 (3,819-4,880)
Experienced non-fatal MVE during the current
annual period; on maintenance dialysis
£6,133 (5,608-6,658)
Latest non-fatal MVE experienced in the
preceding annual period
£738 (351–1,126)
Other vascular disease (defined as with vascular
disease at baseline or experienced latest
non-fatal MVE two or more years previously)
£172 (57–286)
CKD = chronic kidney disease; MVE = major vascular events; CI = confidence interval.
1Predominantly CKD stage 3B (eGFR ≥30 to <45 ml/min/1.73m2).
2Annual costs associated with maintenance dialysis are reduced by £8,802
(8,172-9,432) in years of death.
3Defined at baseline.
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of a major vascular event in the annual period in which
it occurred (£6,133 for those on dialysis and £4,350 for
those not) are substantially higher than the separate ref-
erence costs of vascular events (e.g. the cost for a hos-
pital admission for myocardial infarction in 2011 was
£1,410 and for a stroke in patients on and not on dialysis
was £2,567 and £1,773 respectively [19]). Moreover, ex-
periencing a major vascular event was found to have an
impact on hospital care costs in subsequent years, even
in the absence of further such events.
Renal replacement therapy has a substantially greater
impact on annual hospital costs than vascular events. Al-
though the annual hospital care cost in the year of kidney
transplantation was about 10% greater than the cost in a
year of initiating dialysis, in subsequent years, kidney trans-
plantation was associated with substantially lower hospital
care costs compared to maintenance dialysis.In contrast to previous studies which reported increas-
ing trends in healthcare costs by CKD stage [11,12],
there was no evidence for a difference in annual hospital
care costs between CKD stages 1-3B (mean eGFR = 37.6
mL/min/1.73 m2) and CKD stage 4 in SHARP. Patients
with CKD stage 5 not on RRT were estimated to incur a
small additional cost relative to earlier CKD stages, mainly
attributable to access procedures performed in prepar-
ation for dialysis. There are a number of analytical differ-
ences between the SHARP cost study and previous studies
that might explain this. First, unlike previous studies in
which resource use and costs were summarized according
to each patient’s baseline CKD stage, irrespective of fur-
ther CKD progression, in SHARP costs were attributed to
the actual stage of CKD at the end of each annual period.
Second, in SHARP, the hospital costs of cardiovascular
complications and deaths were evaluated separately from
other hospital care. Third, this SHARP cost analysis fo-
cused on hospital care costs (including routine dialysis
costs), but unlike in previous studies, other healthcare
costs relevant to a CKD population (and increasing with
kidney disease severity) such as costs for routine out-
patient appointments, transport to and from hemodialysis
units, primary care and prescription drugs [3,12-14] were
not included since such information was not collected in
SHARP or, in the case of prescription drugs, the collected
information was not sufficient for costing.
SHARP recruited patients aged 40 years and older with
moderate-to-severe CKD (mostly at stages 3B or worse)
without a prior myocardial infarction or coronary revascu-
larization. Consequently, SHARP is not representative of
the full CKD population where CKD stage 1-3A predomi-
nates and the prevalence of coronary (and other comor-
bidities) is greater and increases with kidney disease
severity [27]. As a consequence, SHARP patients in differ-
ent CKD stages are likely to be more similar than is the
case in the general CKD population. However, the SHARP
estimation framework controls for vascular disease and
diabetes at entry into the study as well as for CKD pro-
gression and cardiovascular disease occurring during
follow-up, and, therefore, the hospital cost estimates cor-
responding to CKD stage and cardiovascular disease, are
likely generalizable to a wider range of moderate-to-severe
CKD adult patients, including those with pre-existing cor-
onary disease.
A further potential limitation is that data on hospital
resource use from the UK and other countries was used
to inform UK costs. Preliminary work found no hetero-
geneity in hospital episode rates between countries con-
ditional on events, except for patients recruited in Asia,
who were excluded. The cost model using only UK pa-
tients produced similar results but was of limited power
(1,935 patients were recruited in the UK). The UK hos-
pital care costs in CKD, presented here, are likely also to
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uting patient data for the analysis, as the respective costs
of hospital services in these countries might differ from
those in the UK.
Conclusions
The UK annual hospital care costs model in moderate-to-
severe CKD presented here identifies renal replacement
therapy, major vascular events and deaths (vascular and
non-vascular) as the key determinants of costs. The model
allows reliable evaluation of effects of interventions and
policies to modify rates of vascular events, progression
of CKD, kidney transplant survival or access to trans-
plantation in this population on hospital costs. To assist
such efforts, a downloadable cost calculator is available at
http://www.herc.ox.ac.uk/downloads/supportingmaterial.
Additional file
Additional file 1: Supplementary material to “What is the impact of
chronic kidney disease stage and cardiovascular disease on the
annual cost of hospital care kidney in moderate-to-severe disease?”.
Abbreviations
CKD: Chronic kidney disease; SHARP: Study of Heart and Renal Protection;
UK: United Kingdom; RRT: Renal replacement therapy; MVE: Major vascular
event; eGFR: Estimated glomerular filtration rate; FCE: Finished consultant
episode.
Competing interests
The study was funded by Merck & Co., Inc. (Whitehouse station, NJ USA),
with additional support from the Australian National Health Medical
Research Council, the British Heart Foundation, and the UK Medical Research
Council. SHARP was initiated, conducted, and interpreted independently of
the principal study funder.
Authors’ contributions
Research idea and study design: BM, SK, WH; data acquisition: SHARP
Collaborative Group; data analysis/interpretation: SK, BM, JLK, IS, WH, ML, CB,
CR, JE, RH, AG, AC; statistical analysis: SK; supervision or mentorship: BM, WH.
Each author contributed important intellectual content during manuscript
drafting or revision and accepts accountability for the overall work by
ensuring that questions pertaining to the accuracy and integrity of any
portion of the work are appropriately investigated and resolved. BM takes
responsibility that this study has been reported honestly, accurately and
transparently; that no important aspects of the study have been omitted,
and that any discrepancies from the study as planned (and, if relevant,
registered) have been explained. All authors read and approved the final
manuscript.
Acknowledgements
The SHARP Collaborative Group comprises: Colin Baigent, Martin J. Landray,
Christina Reith, Jonathan Emberson, David C. Wheeler, Charles Tomson,
Christoph Wanner, Vera Krane, Alan Cass, Jonathan Craig, Bruce Neal, Lixin
Jiang, Lai Seong Hooi, Adeera Levin, Lawrence Agodoa, Mike Gaziano,
Bertram Kasiske, Robert Walker, Ziad A. Massy, Bo Feldt-Rasmussen, Udom
Krairittichai, Vuddidhej Ophascharoensuk, Bengt Fellström, Hallvard Holdaas,
Vladimir Tesar, Andrzej Wiecek, Diederick Grobbee, Dick de Zeeuw, Carola
Grönhagen-Riska, Tanaji Dasgupta, David Lewis, William Herrington, Marion
Mafham, William Majoni, Karl Wallendszus, Richard Grimm, Terje Pedersen,
Jonathan Tobert, Jane Armitage, Alex Baxter, Christopher Bray, Yiping Chen,
Zhengming Chen, Michael Hill, Carol Knott, Sarah Parish, David Simpson,
Peter Sleight, Alan Young, and Rory Collins.
A full list of the SHARP investigators is available elsewhere [15].We thank the SHARP participants and the local clinical center staff, regional
and national coordinators, steering committee, and data monitoring
committee.
Author details
1Health Economics Research Centre (HERC), Nuffield Department of
Population Health, University of Oxford, Oxford, UK. 2Clinical Trial Service Unit
and Epidemiological Studies Unit (CTSU), Nuffield Department of Population
Health, University of Oxford, Oxford, UK. 3Menzies School of Health Research,
Sydney, Australia.
Received: 15 December 2014 Accepted: 10 April 2015References
1. Stevens PE, O’Donoghue DJ, de Lusignan S, Van Vlymen J, Klebe B,
Middleton R, et al. Chronic kidney disease management in the United
Kingdom: NEOERICA project results. Kidney Int. 2007;72(1):92–9.
2. The Renal Association. UK Renal Registry, The Fifteenth Annual Report.
Bristol, UK: UK Renal Registry; 2012.
3. Kerr M, Bray B, Medcalf J, O’Donoghue DJ, Matthews B. Estimating the
financial cost of chronic kidney disease to the NHS in England. Nephrol Dial
Transpl. 2012;27:73–80.
4. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the
incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney
Dis. 2003;42(4):677–84.
5. John R, Webb M, Young A, Stevens PE. Unreferred chronic kidney disease:
a longitudinal study. Am J Kidney Dis. 2004;43(5):825–35.
6. Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH. Longitudinal follow-up
and outcomes among a population with chronic kidney disease in a large
managed care organization. Arch Intern Med. 2004;164(6):659–63.
7. Go AS, Chertow GM, Fan DJ, McCulloch CE, Hsu CY. Chronic kidney disease
and the risks of death, cardiovascular events, and hospitalization. N Engl J
Med. 2004;351(13):1296–305.
8. de Jager DJ, Grootendorst DC, Jager KJ, van Dijk PC, Tomas LMJ, Ansell D,
et al. Cardiovascular and noncardiovascular mortality among patients
starting dialysis. JAMA. 2009;302(16):1782–9.
9. U.S. Renal Data System, USRDS 2012 Annual Data Report: Atlas of Chronic
Kidney Disease and End-Stage Renal Disease in the United States, National
Institutes of Health, National Institute of Diabetes and Digestive and Kidney
Diseases, Bethesda, MD, 2012.
10. Smith DH, Nichols GA, Gullion CM, Johnson ES, Keith D. Predicting costs of
care in chronic kidney disease: the role of comorbid conditions. Journal of
Nephrology: The Internet; 2007. p. 4(1).
11. Honeycutt AA, Segel JE, Zhuo XH, Hoerger TJ, Imai K, Williams D.
Medical costs of CKD in the Medicare population. J Am Soc Nephrol.
2013;24(9):1478–83.
12. Smith DH, Gullion CM, Nichols G, Keith DS, Brown JB. Cost of medical care
for chronic kidney disease and comorbidity among enrollees in a large
HMO population. J Am Soc Nephrol. 2004;15(5):1300–6.
13. Baumeister SE, Boger CA, Kramer BK, Doring A, Eheberg D, Fischer B, et al.
Effect of chronic kidney disease and comorbid conditions on health care
costs: a 10-year observational study in a general population. Am J Nephrol.
2010;31(3):222–9.
14. Vekeman F, Yameogo ND, Lefebvre P, Bailey RA, McKenzie RS, Piech CT.
Healthcare costs associated with nephrology care in pre-dialysis chronic
kidney disease patients. J Med Econ. 2010;13(4):673–80.
15. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C,
et al. The effects of lowering LDL cholesterol with simvastatin plus
ezetimibe in patients with chronic kidney disease (Study of Heart and
Renal Protection): a randomised placebo-controlled trial. Lancet.
2011;377(9784):2181–92.
16. SHARP Collaborative Group. Study of Heart and Renal Protection (SHARP):
randomized trial to assess the effects of lowering low-density lipoprotein
cholesterol among 9,438 patients with chronic kidney disease. Am Heart J.
2010;160(5):785-794–e710.
17. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology
Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates,
lower CKD prevalence estimates, and better risk predictions. Am J Kidney
Dis. 2010;55(4):622–7.
Kent et al. BMC Nephrology  (2015) 16:65 Page 8 of 818. Jameson S, Reed MR. Payment by results and coding practice in the
National Health Service. The importance for orthopaedic surgeons. J Bone
Joint Surg Br. 2007;89(11):1427–30.
19. Department of Health. NHS Reference Costs 2010-11. Leeds: Department of
Health; 2011. URL: https://www.gov.uk/government/publications/2010-11-
reference-costs-publication [Accessed April 20, 2015].
20. National Institute for Health and Clinical Excellence (NICE): Guide to the
methods of technology appraisal 2013. April 2013. Available from:
http://publications.nice.org.uk/pmg9 [Accessed April 20, 2015]
21. Daidone S, Street A. Estimating the costs of specialised care. In: Centre for
health economics discussion papers. UK: Centre for Health Economics,
University of York; 2011.
22. NHS Kidney Care. Kidney dialysis - developing costs to deliver an equitable
and high-quality service. 2009.
23. Manning WG, Mullahy J. Estimating log models: to transform or not to
transform? J Health Econ. 2001;20(4):461–94.
24. Rogers WH. Regression standard errors in clustered samples. Stata Tech Bull.
1993;13:19–23.
25. Altman DG, Vergouwe Y, Royston P, Moons KGM. Prognosis and prognostic
research: validating a prognostic model. Brit Med J. 2009;338:1423–35.
26. R Development Core Team (2013). R: A language and environment for
statistical computing. R Foundation for Statistical Computing, Vienna,
Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.
27. Stevens LA, Li S, Wang C, Huang C, Becker BN, Bomback AS, et al.
Prevalence of CKD and comorbid illness in elderly patients in the United
States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney
Dis. 2010;55(3 Suppl 2):S23–33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
